Company news
Jiangsu Yahong Meditech Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Announcement on Resolution of the 2024 Annual General Meeting
May 23, 2025
Report for Q1 2025
April 29, 2025
Announcement on Attending the 2024 SSE STAR Market Innovative Drug Industry Collective Performance Briefing and Q1 2025 Performance Briefing
April 25, 2025
Special Report on Deposit and Actual Use of Raised Funds in 2024
April 18, 2025
Announcement on Voluntary Disclosure Regarding the Completion of First Subject Enrollment in Phase Ⅰa Clinical Trial for APL-2302
March 13, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 27, 2025
Announcement on Voluntary Disclosure on Phase II Clinical Trial Data of Oral APL-1202 Combined with Tislelizumab in Neoadjuvant Therapy for Muscle-invasive Bladder Cancer at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium
February 14, 2025
Announcement on Adjustment of Core Technical Personnel
February 7, 2025
Announcement on Opening Special Settlement Accounts for the Cash Management of Raised Funds
January 22, 2025
Announcement on Using Some Temporarily Idle Raised Funds for Cash Management
January 17, 2025
Announcement on the Voluntary Disclosure of the Approval of the Clinical Trial Application for APL-2302 by the National Medical Products Administration
January 16, 2025
Announcement on Implementation Results of Share Repurchase
December 27, 2024
Announcement on Progress in Repurchasing Shares through Call Auction
December 2, 2024
Announcement on Voluntary Disclosure of Releasing Relevant Data of APL-1702 International Multicenter Phase III Clinical Trial at IPVC 2024
November 12, 2024
Announcement on Voluntary Disclosure of Approval for APL-1706 by National Medical Products Administration
November 5, 2024
Announcement on Completion of Industrial and Commercial Registration for Changes in Business Scope and Renewal of Business License
October 29, 2024
Announcement on Voluntary Disclosure of FDA Approval for Clinical Trial of APL-2302
October 24, 2024
Announcement on Change of Sponsor Representative for Continuous Supervision
October 21, 2024
Announcement on Correction of Resolution of the 11th Meeting of the 2nd Board of Directors
September 29, 2024
Announcement on Voluntary Disclosure of Release of Relevant Data of APL-1702 International Multicenter Phase III Clinical Trial at the 27th National Conference on Clinical Oncology and 2024 Annual Meeting of Chinese Society of Clinical Oncology
September 27, 2024
Announcement on Voluntarily Disclosure of Phase II Clinical Trial Results of Oral APL-1202 Combined with Tislelizumab in Neoadjuvant Therapy for Muscle-invasive Bladder Cancer
September 25, 2024